值得注意的是，今年2月，中国中药发布公告称，国药集团拟以每股4.6港元的价格将中国中药私有化。根据国药集团的相关持股比例计算，此次私有化的总代价约为154.5亿港元。对于此次私有化的原因，中国中药认为由于二级市场的交易量有限，其作为上市公司融资平台功能存在受限。China Traditional Chinese Medicine (00570) has risen nearly 5%, with a cumulative increase of more than 15% this month. As of press time, it has risen by 4.97%, closing at HKD 3.8, with a turnover of 0.143 billion HKD.
According to the Wisdom Financial APP, China Traditional Chinese Medicine (00570) has risen nearly 5%, with a cumulative increase of more than 15% this month. As of press time, it has risen by 4.97%, closing at HKD 3.8, with a turnover of 0.143 billion HKD.
Huachun Securities pointed out that in terms of generic drugs, although the catalogue announcement may be delayed, it is not expected to be absent. Considering that the growth rate of exclusive generic drugs is far higher than that of non-generic drugs, it is expected that the market will repeatedly play the main line of generic drugs in the future. In addition, since the adjustment of the assessment system of central enterprises this year, ROE indicators will be more valued, which is expected to drive significant improvement in fundamentals.
It is worth noting that in February this year, China Traditional Chinese Medicine announced that China National Pharmaceutical Group Corporation (Sinopharm) plans to privatize China Traditional Chinese Medicine at a price of HKD 4.6 per share. According to the relevant shareholding ratio of Sinopharm, the total cost of this privatization is about 15.45 billion HKD. China Traditional Chinese Medicine believes that due to the limited trading volume in the secondary market, its function as a financing platform for listed companies is restricted.
